WO2001076565A1 - Compositions et preparations se desintegrant dans la cavite buccale - Google Patents
Compositions et preparations se desintegrant dans la cavite buccale Download PDFInfo
- Publication number
- WO2001076565A1 WO2001076565A1 PCT/JP2001/003114 JP0103114W WO0176565A1 WO 2001076565 A1 WO2001076565 A1 WO 2001076565A1 JP 0103114 W JP0103114 W JP 0103114W WO 0176565 A1 WO0176565 A1 WO 0176565A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- orally disintegrating
- drugs
- lubricant
- composition according
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to an orally disintegrating composition and an orally disintegrating preparation, and more particularly, to an orally disintegrating composition having the strength required for handling the preparation and rapidly disintegrating in the oral cavity.
- the present invention relates to a product, and an orally disintegrating preparation using the same. Background art
- Japanese Patent Publication No. Sho 62-50445 discloses gelatin, dextrin, hydrolyzed dextrin or alginate, or one or more of the above substances and polyvinyl alcohol, polyvinyl pyrrolidine or A network of pharmaceutically acceptable water-soluble or water-dispersible polymer simple substance selected from a mixture of arabia gum, a mixture of polyvinyl alcohol and polyvinyl pyrrolidine, or a mixture of gum arabic and polyvinyl pyrrolidine, Then, solid pharmaceutical dosage forms for oral administration having a density of 10 to 200 mg / m 1 are described.
- International Publication WO93Z1276969 discloses that an active ingredient and a saccharide consisting of lactose and Z or mannitol, and a solid component containing 0.1 to 1.2 wZw% of agar.
- An orally disintegrating solid preparation having a sufficient density for handling the preparation having a density of 400 mg Zm 1 to 100 mg Zm 1 is described.
- this method for producing a solid preparation involves pouring a suspension into a mold and drying the suspension, which is different from a general method for producing tablets, and has a problem that it is complicated.
- Japanese Patent Application Laid-Open No. 9-48772 / 26 discloses that a substance consisting of a drug and a substance which moisturizes by humidification so as to be moldable and maintains the shape by drying after molding is formed, and these components are humidified and molded at a low density. Thus, a rapidly disintegrating preparation in the oral cavity which is easily disintegrated is described.
- Japanese Patent Application Laid-Open No. 8-229101 discloses a tablet in the form of a tablet in a dry state containing a drug, a water-soluble binder and a water-soluble excipient.
- a tableting process of pressing at a minimum necessary low pressure and a humidifying process for absorbing moisture into the tablet formed in the tableting process
- a drying step of drying the tablet humidified in the humidification step In order to obtain a hardness that can maintain its form when transferring to a tableting process, a tableting process of pressing at a minimum necessary low pressure, and a humidifying process for absorbing moisture into the tablet formed in the tableting process And a drying step of drying the tablet humidified in the humidification step.
- any preparation or production method requires a step of humidifying the molded product, and in this humidification step, the tablet becomes bloated, the appearance of the tablet is impaired, and the commercial value is reduced.
- Japanese Patent Application Laid-Open No. 5-271054 describes a method for producing an orally dissolvable tablet in which a mixture containing a pharmaceutically active ingredient, a saccharide, and a water containing such moisture that the particle surface of the saccharide is moistened is obtained.
- this manufacturing method uses a wet tableting method in which water is forcibly added to the mixture for tableting and tableting is performed in a wet state. Is not enough.
- European Patent Application Publication EP 0 590 063 A1 which is classified into the wet tableting method.
- Very specific manufacturing equipment is used to overcome the obstacles, which involves manufacturing costs and productivity issues.
- the manufacturing methods described in International Publication W095 / 3242900 and International Publication W093 / 15742 are both classified as wet tableting, but special shaping is required. There are problems when the agent is used or the productivity is low.
- JP-B-58-24410 discloses that tablet contents are mixed with a solvent which is inert to the tablet contents and which is frozen at a temperature of 30 ° C. to + 25 ° C. Make up 5 to 80% by weight of the mixture, solidify the mixture by placing it in an inert cooling medium and compress into tablets at a temperature below the freezing point of the solvent. Evaporate the solvent by freeze-drying or air-drying A method for producing a porous tablet having good disintegration properties is described. Also, Japanese Patent Application Laid-Open No. 3-86867 describes that a composition comprising a water-soluble or hydratable gel or a foamy substance is kept at about 0 ° C or below until substantially all water is removed. A readily dissolvable carrier material with sufficient strength, which is obtained by contact with an anhydrous liquid desiccant such as absolute ethanol at the following temperatures, is described.
- Japanese Patent Application Laid-Open No. Hei 8-310751 describes a fast-dissolving edible unit that mixes an uncured shear matrix with a controlled-release system, and forms and cures. Specifically, an amorphous saccharide must be used as the uncured shearing type matrix, and such an amorphizing treatment is complicated.
- JP-A-2-32014 describes a solid preparation in the form of a wet tablet suitable for oral administration. However, a spray-drying step, followed by ethanol Z water or a wet mass with water alone. Is prepared and put into a mold and dried to obtain tablets. Therefore, it is expected that the production process is complicated and the productivity is low. Also, Japanese Patent Application Laid-Open No.
- Sho 61-158830 Describes an antacid composition having a porous ultrafine crystal structure containing a confectionery base material containing an antacid and a confectionery sweetener and a plasticizer, but the production method is complicated and the production is complicated. There is a problem with gender. Disclosure of the invention
- the present invention has been made in view of the above-mentioned problems of the related art, and has as its object to have an appropriate strength required for handling of a pharmaceutical preparation, and to promptly in the oral cavity.
- Disintegrating orally disintegrating composition and disintegrating orally disintegrating preparation are provided.
- Another object of the present invention is to provide an orally disintegrating composition and an orally disintegrating preparation having the above-mentioned excellent properties substantially without the need for complicated processes and special equipment.
- the tableting process is performed in a dry state to enable production.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, using a specific excipient and a disintegrant, adding a specific lubricant to a mixture or a granulated product thereof, and performing tableting. By doing so, it was unexpectedly found that a composition having appropriate strength not to be broken in the manufacturing process, storage and distribution process and having rapid disintegration in the oral cavity can be obtained. It was completed.
- the orally disintegrating composition is a molded composition that disintegrates rapidly in the oral cavity, and comprises an excipient composed of a sugar alcohol, a disintegrant, and a lubricant. permeation rate of the ethanol on the 3. 0 X 1 0- 3 g It is characterized by being longer than sec.
- the penetration rate of the ethanol on the lubricants 5. It is desirable that 0 X 1 0 one 3 g 2 Z sec or more.
- a preferred form of the orally disintegrating composition of the present invention is characterized in that the lubricant is oral isine and Z or sodium stearyl fumarate, or stearic acid and / or talc.
- the orally disintegrating composition of the present invention is characterized in that the sugar alcohol is mannitol and Z or erythritol.
- the disintegrant is a low-substituted hydroxypropylcellulose, crystalline cellulose, hydroxypropyl starch, carboxymethylsuccinic sodium, wheat starch, rice starch, corn starch and potato starch.
- At least one poorly water-soluble binding disintegrant selected from the group consisting of: croscarmellose sodium, carmellose calcium, crospovidone, magnesium aluminate hydroxide, magnesium carbonate and phosphoric acid At least one member selected from the group consisting of calcium dihydrogen There is a feature.
- the excipient is 32 to 99.2%, the disintegrant is 0.5 to 60%, and the lubricant is 0. It is characterized by being blended at a ratio of 3 to 8.0%.
- Still another preferred embodiment of the orally disintegrating composition of the present invention has a tablet strength of 20 N or more, and has an orally disintegrating time of 90 seconds or less in a healthy adult. Preferably it is.
- the orally disintegrating preparation of the present invention is characterized in that a medicinal component is added to the orally disintegrating composition as described above.
- the medicinal component includes a central nervous system drug, Peripheral nervous system drugs, sensory organ drugs, allergic drugs Medications, cardiovascular drugs, respiratory drugs, gastrointestinal drugs, hormonal drugs, urogenital and anal drugs, vitamins, nourishing tonics, blood and body fluid drugs, metabolic drugs, cells Use inducing drugs, oncology drugs, diagnostic drugs, drugs for physical disorders, antibiotics, chemotherapeutics, biological drugs, drugs for bioactive peptides or parasites, and any combination of these drugs Can be done.
- the orally disintegrating composition of the present invention is typically a non-porous compression-molded composition, and includes an excipient composed of a sugar alcohol, a disintegrant, and a predetermined lubricant. It contains.
- the excipient those which are water-soluble and have a suitable sweetness and coolness are preferable, and various sugar alcohols can be used.
- mannitol or erythritol and a mixture thereof are preferably used. It is particularly desirable to use a mannitol.
- disintegrants include poorly water-soluble disintegrants that also have binder-like properties, such as hydroxypropyl starch, low-substituted hydroxypropyl cellulose, crystalline cellulose, carboxymethyl starch sodium, wheat starch, Rice starch, corn starch or potato starch and any mixtures thereof can be used.
- binder-like properties such as hydroxypropyl starch, low-substituted hydroxypropyl cellulose, crystalline cellulose, carboxymethyl starch sodium, wheat starch, Rice starch, corn starch or potato starch and any mixtures thereof can be used.
- the binder is not an essential component.
- ordinary disintegrants having no binder-like properties for example, croscarmellose sodium, carmellose calcium, Povidone, magnesium aluminate hydroxide, magnesium carbonate or calcium dihydrogen phosphate and any mixtures thereof can also be used.
- the predetermined lubricant used in the present invention has a function of facilitating infiltration of water into the composition when the disintegrable composition disintegrates in the oral cavity, and the ethanol is added to the lubricant.
- permeation rate 3. 0 X 1 0- 3 g 2 not more than Z seconds corresponds.
- leucine sodium stearyl fumarate, talc, and stearic acid.
- Leucine and sodium stearyl fumarate can be suitably used, and these can be used alone or in combination of two or more. It is possible to
- the use of per se as rate of penetration of ethanol even lubricant is less than 3. 0 X 1 0 one 3 g 2 seconds, such as stearic acid mug Neshiumu being frequently used conventionally Undesirably, the use of such lubricants leads to prolonged disintegration time of the composition or formulation.
- lubricants such as magnesium stearate, calcium stearate, stearyl alcohol, hydrogenated vegetable oil, macrogol, sucrose fatty acid ester, and the like, as long as they do not deviate from the penetration rate of ethanol described above.
- Light silicic anhydride, sodium lauryl sulfate, sodium benzoate, hydrous silicon dioxide, glyceryl phosphate, etc. can be used in combination with leucine, etc., especially magnesium stearate, calcium stearate, hydrogenated vegetable oil And sucrose fatty acid ester and light gay anhydride can be preferably used in combination.
- Anti-adhesion ability A function to prevent powder from adhering to the contact surface with the equipment during powder molding. Can be.
- the mixing ratio of each of the above components in the orally disintegrating composition of the present invention is not particularly limited, but it is preferable to formulate such that tablet strength and orally disintegrating time described below can be realized.
- the above excipients are
- the amount is preferably 10 to 40%, and when crystalline cellulose or hydroxypropylstarch is used, The amount is 1
- 0 to 60% is an appropriate amount.
- the compounding amount is preferably 0.5 to 5%.
- the appropriate amount is 2 to 20%.
- the essential components of the orally disintegrating composition of the present invention are an excipient composed of the above-mentioned sugar alcohol, a binding disintegrant or a usual disintegrant, and a predetermined lubricant. As long as other properties are not adversely affected, it is possible to include various additives commonly used in tablet production.
- Such additives include, for example, binders, sweeteners, flavors, coloring agents, and the like.
- Binders include gum arabic, sodium alginate, bierpyrrolidone and pullulan.
- Sweeteners include aspartame Acesulfame K, etc.
- Flavors include lemon lime, o Range and menthol.
- Examples of the coloring agent include Food Yellow No. 5, Food Red No. 5, edible lake pigment, yellow iron sesquioxide and the like.
- additives can be used alone or in combination of two or more. Further, these additives can be added at any stage of the production process of the present composition described later.
- the orally disintegrating composition of the present invention described above has excellent properties, typically has a tablet strength of 20 N or more, and usually has an orally disintegrating time of 90 seconds or less in healthy adults. Preferably, it is within 40 seconds, more preferably within 30 seconds.
- composition or preparation of the present invention has the necessary strength for handling the preparation, and exhibits excellent performance of rapidly disintegrating in the oral cavity.
- the orally disintegrating composition of the present invention is obtained by mixing the above-mentioned excipient, binding disintegrant (or ordinary disintegrant) and a predetermined lubricant, and then tableting. Tableting after granulation, or drying after excipient and binding disintegrant (or ordinary disintegrant) after wet granulation, mixing dry granulated product with specified lubricant It is manufactured by three general manufacturing methods, and does not require special manufacturing equipment.
- the method of mixing, granulating, drying and tableting is not particularly limited, but it is necessary to make the mixture or granulated material for tableting substantially dry. .
- the orally disintegrating preparation of the present invention is obtained by adding a medicinal ingredient to the orally disintegrating composition described above, and has, in principle, the same properties as the composition of the present invention.
- the medicinal components include drugs for central nervous system, drugs for peripheral nervous system, drugs for sensory organs, drugs for allergies, drugs for circulatory organs, drugs for respiratory organs, drugs for digestive organs, hormones, urogenital organs And anal drugs, vitamins, nourishing tonics, blood and body fluids, metabolic drugs, cell stimulants, oncology drugs, diagnostic drugs, physical disorders, antibiotics, chemotherapeutics And biological agents, bioactive peptides, drugs against parasites, and the like. If necessary, one or more of these medicinal ingredients can be used in combination.
- the compounding amount of the above-mentioned medicinal ingredient depends on the nature of the medicinal ingredient. It is desirable to set it to 0.03 to 20%.
- the compounding amount of the medicinal component exceeds 80%, a favorable balance between the orally disintegrating property of the final product and the tablet strength cannot be obtained, which is not preferable.
- the preparation of the present invention is in the form of a solid preparation, typically in the form of a tablet, but can be subjected to masking such as bitterness masking by a conventionally known method.
- Such masking can be carried out by applying the active ingredient or granules of the medicinal ingredient and compressing it.
- the preparation of the present invention can be produced in the same manner as in the above-mentioned method for producing the composition of the present invention.
- the medicinal component may be added before the above tableting.
- Fig. 1 is a graph showing the relationship between the oral disintegration time of a hydroxypropyl starch-based tablet and the penetration rate of ethanol into the lubricant used in the tablet.
- Fig. 2 is a graph showing the low-substituted hydroxypropylcellulose-based formulation.
- FIG. 3 is a graph showing the relationship between the oral disintegration time of a tablet and the penetration rate of ethanol into the lubricant used in the tablet.
- FIG. 3 shows the oral disintegration time of the crystalline cellulose-based prescription tablet and the lubricant used in the tablet.
- Fig. 4 is a graph showing the relationship between the disintegration time in the oral cavity, the type of lubricant, and the number of revolutions in lubrication for hydroxypropyl starch-based tablets. It is.
- lubricants are abbreviated as follows.
- L eucine ⁇ L bite isine, Mg-St ... magnesium stearate, Ca_St ... calcium stearate, SSF ... sodium stearyl fumarate, Talc ... talc, SEFA ... sucrose fatty acid ester, St ... BEST MODE FOR CARRYING OUT THE INVENTION
- HPS-101 (trade name of Freund Corporation) was used for hydroxypropyl succinic acid and Avicel PH-102 (trade name, manufactured by Asahi Kasei Corporation) for crystalline cellulose.
- Avicel PH-102 (trade name, manufactured by Asahi Kasei Corporation) for crystalline cellulose.
- L-HPC (LH-21) (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) was used for low-substituted hydroxypropylcellulose. [Tablet strength]
- an automatic surface tension meter manufactured by KRUSS GmbH, type; K122 was used. Fill the lubricant sample of interest in a sample holder with an inner diameter of 1.2 cm with a sufficient amount necessary for measurement. After that, the sample in the holder is compressed by a cylinder with a load of 200 g for 10 seconds and used for measurement.
- Ethanol was used as the penetration solvent. The measurement was performed three times, and the permeation rate was calculated for the average curve.
- the permeation rate of the liquid into the powder is expressed by L 2 / t (L 2 ) in the equation of Washburn (Washburn, E.W .: Pys.Rev., 2_7_273 (1921)). Is the distance of the liquid surface permeating into the powder layer, and t is the time.)
- W 2 Z t with the increase in the weight of the permeated liquid instead of the liquid permeation distance L [gsec] was defined as the permeation rate.
- the penetration rate of ethanol was measured for the seven lubricants by the method described above. Table 1 shows the obtained results. Since the sucrose fatty acid ester and stearic acid were dissolved in ethanol, ethanol that had been saturated with sucrose fatty acid ester and stearic acid in advance was used as the permeate. Lubricants
- binding disintegrant is hydroxypropyl starch
- One of the above lubricants was selected and added to 14.45 g of the obtained granules in an amount of 3% (0.45 g) based on the total weight.
- the granules are filled in a container with a lid, and the container is subjected to a 50-turn treatment with Willy A. Bachofen AG Macchinenfabriktype: T 2 C, and the lubricant is formed into granules. The lubrication was performed.
- the lubricated granules were compressed using a hydraulic press at a pressure such that the tablet hardness was about 20 to 3 ON, and formed into tablets.
- the tablet shape is a flat-cornered tablet with a diameter of 7.94 mm and a weight of 200 mg.
- the above tablets were evaluated for their performance, and the results are shown in Table 2.
- a lubricant using Mg stearate, Ca stearate or sucrose fatty acid ester as a lubricant corresponds to a formulation outside the scope of the present invention.
- binding disintegrant is crystalline cellulose
- 70 g of mannitol powder passed through a sieve having an aperture of 800 m (20 mesh) and 30 g of a crystal cell mouth were mixed in a mortar for about 5 minutes.
- 20 ml of purified water was added, mixed for about 5 minutes to granulate, and then passed through a sieve having an opening of 170 m (10 mesh).
- the dried mixture was sieved through a sieve having an opening of 600 m (28 mesh) to obtain granules.
- the horizontal axis shows the disintegration time of the tablet in the oral cavity
- the vertical axis shows the permeation rate of ethanol to the lubricant used in the tablet. Shown in
- leucine permeation rate Ru der 5 X 1 0- 3 g 2 or Z seconds, talc, stearic acid, the group intraoral disintegration time shortest in sodium stearyl fumarate are all prescription system (Within 30 seconds) and proved to be useful for reducing the oral disintegration time.
- mannitol and hydroxypropyl starch were added in the composition shown in Table 5, and mixed for about 3 minutes.
- 6 ml of purified water was added to 39.2 g of the obtained mixture, mixed for about 2 minutes, and dried at 60 ° C for 2 hours.
- the dried mixture was sized through a sieve having a mesh size of 600 m, and sodium stearyl fumarate was further added and mixed. Hydraulic Using a press, the mixture was compressed at a pressure of 19'8 MPa and formed into tablets.
- the obtained tablet is a flat-corner tablet with a diameter of 7.94 mm and a weight of 200 mg.
- Example 4 The same operation as in Example 4 was repeated to obtain tablets. However, the mixing ratio of mannitol and hydroxypropyl starch was in accordance with Table 6, and tablets were molded at a pressure of 139 MPa. The obtained tablets were evaluated for the performance described above, and the obtained results are shown in Table 20. Table 6
- Example 4 The same operation as in Example 4 was repeated to obtain tablets.
- the proportions of mannitol and hydroxypropyl starch were in accordance with Table 7, and tablets were molded at a pressure of 119 MPa.
- the obtained tablets were evaluated for the performance described above, and the obtained results are shown in Table 20.
- Table 7 The proportions of mannitol and hydroxypropyl starch were in accordance with Table 7, and tablets were molded at a pressure of 119 MPa.
- Table 7 Table 7
- a tablet was obtained in the same manner as in Example 4, except that hydroxypropyl starch was replaced by low-substituted hydroxypropylcellulose.
- the amount of purified water to be added is 10 m 1
- the tablet forming pressure is 99 MPa.
- Example 7 The same operation as in Example 7 was repeated to obtain tablets. However, the mixing ratio of mannitol and low-substituted hydroxypropylcellulose was in accordance with Table 9, and tablets were molded at a pressure of 59 MPa.
- Example 7 The same operation as in Example 7 was repeated to obtain tablets. However, the mixing ratio of mannitol and low-substituted hydroxypropylcellulose was in accordance with Table 10, and tablets were molded at a pressure of 79 MPa.
- tablets were obtained by performing the same operation as in Example 5 except that crystalline cellulose was used instead of hydroxydipropyl starch.
- the amount of purified water added in this case is 8 m 1
- the tablet forming pressure is 59 MPa.
- Example 12 As shown in Table 12, the same operation as in Example 5 was carried out except that erythritol was used instead of mannitol, to obtain tablets. However, in this case, the amount of purified water to be added was 6 m1, and the tablet molding pressure was 119 MPa. It was shown to. Table 1 2
- Example 11 The same operation as in Example 11 was repeated to obtain tablets. However, the blending ratio of erythritol / hydroxypropyl starch was in accordance with Table 13, and tablets were molded at a pressure of 79 MPa.
- Example 14 As shown in Table 14, the same operation as in Example 7 was carried out except that erythritol was used instead of mannitol, to obtain tablets. However, in this case, the amount of purified water to be added is 8 m 1, and the tablet forming pressure is 139 MPa. The above tablets were evaluated for the performance described above, and the obtained results are shown in Table 20. Table 14
- Example 13 The same operation as in Example 13 was repeated to obtain a tablet.
- the blending ratio is in accordance with Table 15, the amount of purified water added is 10 m 1, and the tablet forming pressure is 59 MPa.
- Example 13 The same operation as in Example 13 was repeated to obtain a tablet.
- the mixing ratio is in accordance with Table 16, the amount of purified water added is 8 ml, and the tablet forming pressure is 40 MPa.
- Example 17 a tablet was obtained by performing the same operation as in Example 10 except that erythritol was used instead of mannitol.
- a tablet was obtained in the same manner as in Example 4, except that croscarmellose sodium was used instead of hydroxypropyl starch.
- the mixing ratio is in accordance with Table 18, and the amount of purified water added in this case is 6 m1, and the tablet forming pressure is 158 MPa.
- SSF sodium stearyl fumarate
- Mg_St magnesium stearate
- the granules are filled into a container with a lid, and the container is turned upside down 10 times (rotation method in which the lid and the bottom are reversed), 2 10 times inverted turning with inclination, 3 10 times inverted turning Was subjected to a rotation treatment to make a set, and the lubricant was lubricated by blending the lubricant SSF or Mg-St with the granules.
- the total number of revolutions at this time is 30 XN (number of sets).
- Table 21 shows the rotation speed for each example.
- the lubricated granules were compressed at a pressure such that the tablet hardness was about 40 N, as shown in Table 21, and formed into tablets.
- the tablet shape is the same as in Example 4.
- Example 19 24 using SSF the disintegration time of the tablet in the oral cavity was reduced by about 10 seconds compared to Comparative Example 13 using Mg-St. You can see that. In addition, since the tablet hardness of each case was made uniform, it is considered that such a difference is caused by the addition of SSF.
- SSF was added to the granules at a rate of 1%, and as described above, using a container with a lid, (1) 40 times of inverted rotation, (2) 40 times of inverted rotation, and (3) 40 times of inverted rotation. After subjecting to a spinning process with one set of inverted rotation, lubricating the SSF by blending it into granules, it was press-molded at the tableting pressure shown in Table 22 and the same tablets as in Example 4. A tablet of this example having a shape was obtained.
- Comparative Example 5 Although an orally disintegrating tablet having good properties was obtained, it was necessary to apply a special production method requiring low-pressure tableting and humidification and drying of the tablet. Remained. In addition, since the formulation of Comparative Example 4 and Comparative Example 5 is the same, if the usual manufacturing method is applied, an orally disintegrating tablet having good properties may be obtained depending on the formulation of Comparative Example 5. It is clear that it cannot be obtained.
- Example 4 The same operation as in Example 4 was repeated. L-leucine and magnesium stearate are used as lubricants instead of sodium stearyl sodium fumarate. Used. The mixing ratio was in accordance with Table 23, and tablets were molded under a pressure of 178 MPa.
- Table 25 shows the results of the above-mentioned performance evaluation of the obtained tablets.
- Example 4 The same operation as in Example 4 was repeated. However, talc and calcium stearate were used as lubricants instead of sodium stearyl fumarate.
- the mixing ratio was in accordance with Table 24, and tablets were molded at a pressure of 178 MPa.
- an orally disintegrating composition and an orally disintegrating preparation which have appropriate strength required for handling the preparation and which rapidly disintegrate in the oral cavity.
- an orally disintegrating composition or preparation having excellent properties can be easily obtained by a general production method without requiring special equipment.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001574083A JP4802436B2 (ja) | 2000-04-12 | 2001-04-11 | 口腔内崩壊型組成物及び口腔内崩壊型製剤 |
AU2001248751A AU2001248751A1 (en) | 2000-04-12 | 2001-04-11 | Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-110396 | 2000-04-12 | ||
JP2000110396 | 2000-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001076565A1 true WO2001076565A1 (fr) | 2001-10-18 |
Family
ID=18622916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003114 WO2001076565A1 (fr) | 2000-04-12 | 2001-04-11 | Compositions et preparations se desintegrant dans la cavite buccale |
Country Status (3)
Country | Link |
---|---|
JP (2) | JP4802436B2 (ja) |
AU (1) | AU2001248751A1 (ja) |
WO (1) | WO2001076565A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004315483A (ja) * | 2003-02-28 | 2004-11-11 | Towa Yakuhin Kk | 口腔内崩壊錠剤 |
JP2004339071A (ja) * | 2003-05-13 | 2004-12-02 | Towa Yakuhin Kk | 苦味を低減した口腔内崩壊錠剤 |
JP2005060309A (ja) * | 2003-08-13 | 2005-03-10 | Towa Yakuhin Kk | 不快な味を低減した口腔内崩壊錠剤 |
JP2005306770A (ja) * | 2004-04-21 | 2005-11-04 | Toa Eiyo Ltd | 口腔内速崩壊型製剤及びその製造方法 |
WO2008133330A1 (ja) | 2007-04-26 | 2008-11-06 | Toray Industries, Inc. | 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤 |
WO2008120548A3 (ja) * | 2007-03-13 | 2008-12-18 | Dainippon Sumitomo Pharma Co | 口腔内崩壊錠 |
WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
JP2010155865A (ja) * | 2003-02-28 | 2010-07-15 | Towa Yakuhin Kk | 口腔内崩壊錠剤 |
WO2010092828A1 (ja) * | 2009-02-12 | 2010-08-19 | 富士化学工業株式会社 | 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物 |
JP2011513194A (ja) * | 2008-02-29 | 2011-04-28 | 大塚製薬株式会社 | 口腔内崩壊錠 |
WO2011121823A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
WO2011121824A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 口腔内崩壊錠 |
US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
US8642648B2 (en) | 2011-01-17 | 2014-02-04 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
US8980316B2 (en) | 2005-05-18 | 2015-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Stable tablet containing droxidopa |
US9314454B2 (en) | 2007-12-28 | 2016-04-19 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
WO2017115764A1 (ja) * | 2015-12-28 | 2017-07-06 | 日本新薬株式会社 | 圧縮成型製剤 |
WO2019146642A1 (ja) * | 2018-01-24 | 2019-08-01 | 大原薬品工業株式会社 | γ-アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
CN104519874B (zh) * | 2012-06-05 | 2018-08-03 | 武田药品工业株式会社 | 固体制剂 |
KR20160030093A (ko) | 2013-07-19 | 2016-03-16 | 가부시키가이샤산와카가쿠켄큐쇼 | 구강 내 붕괴정 |
GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
WO2017064815A1 (ja) * | 2015-10-16 | 2017-04-20 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
JP6858575B2 (ja) * | 2016-01-29 | 2021-04-14 | 沢井製薬株式会社 | ナルフラフィン含有口腔内崩壊錠 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03227916A (ja) * | 1990-02-02 | 1991-10-08 | Ss Pharmaceut Co Ltd | 発泡性製剤組成物 |
JPH09194381A (ja) * | 1996-01-17 | 1997-07-29 | Kowa Co | カルシウム塩含有チュアブル錠 |
JPH10287555A (ja) * | 1997-04-14 | 1998-10-27 | Kowa Co | チュアブル錠 |
JP2000178182A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 崩壊性組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2919771B2 (ja) * | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
DK0922464T3 (da) * | 1996-07-12 | 2005-06-06 | Daiichi Seiyaku Co | Hurtigt desintegrerbare, kompressionsstöbte materialer og fremgangsmåder til fremstilling af samme |
JPH10182436A (ja) * | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | 固形医薬製剤 |
JPH10298062A (ja) * | 1997-04-24 | 1998-11-10 | Pfizer Pharmaceut Co Ltd | 口腔内速溶型錠剤 |
DK1561458T3 (da) * | 1998-07-28 | 2010-10-25 | Takeda Pharmaceutical | Hurtigt henfaldende fast middel |
JP4504467B2 (ja) * | 1998-07-30 | 2010-07-14 | 佐藤製薬株式会社 | 口腔内崩壊性錠剤 |
WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
-
2001
- 2001-04-11 WO PCT/JP2001/003114 patent/WO2001076565A1/ja active Application Filing
- 2001-04-11 JP JP2001574083A patent/JP4802436B2/ja not_active Expired - Fee Related
- 2001-04-11 AU AU2001248751A patent/AU2001248751A1/en not_active Abandoned
-
2011
- 2011-06-16 JP JP2011134262A patent/JP2011225588A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03227916A (ja) * | 1990-02-02 | 1991-10-08 | Ss Pharmaceut Co Ltd | 発泡性製剤組成物 |
JPH09194381A (ja) * | 1996-01-17 | 1997-07-29 | Kowa Co | カルシウム塩含有チュアブル錠 |
JPH10287555A (ja) * | 1997-04-14 | 1998-10-27 | Kowa Co | チュアブル錠 |
JP2000178182A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 崩壊性組成物 |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010155865A (ja) * | 2003-02-28 | 2010-07-15 | Towa Yakuhin Kk | 口腔内崩壊錠剤 |
JP2004315483A (ja) * | 2003-02-28 | 2004-11-11 | Towa Yakuhin Kk | 口腔内崩壊錠剤 |
JP4551627B2 (ja) * | 2003-02-28 | 2010-09-29 | 東和薬品株式会社 | 口腔内崩壊錠剤の製造方法 |
JP2004339071A (ja) * | 2003-05-13 | 2004-12-02 | Towa Yakuhin Kk | 苦味を低減した口腔内崩壊錠剤 |
JP2005060309A (ja) * | 2003-08-13 | 2005-03-10 | Towa Yakuhin Kk | 不快な味を低減した口腔内崩壊錠剤 |
JP2005306770A (ja) * | 2004-04-21 | 2005-11-04 | Toa Eiyo Ltd | 口腔内速崩壊型製剤及びその製造方法 |
US8980316B2 (en) | 2005-05-18 | 2015-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Stable tablet containing droxidopa |
WO2008120548A3 (ja) * | 2007-03-13 | 2008-12-18 | Dainippon Sumitomo Pharma Co | 口腔内崩壊錠 |
JPWO2008120548A1 (ja) * | 2007-03-13 | 2010-07-15 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
US9980915B2 (en) | 2007-03-13 | 2018-05-29 | Sumitomo Dainippon Pharma Co., Ltd. | Oral disintegrating tablet |
JP5537927B2 (ja) * | 2007-03-13 | 2014-07-02 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
US8778392B2 (en) | 2007-03-13 | 2014-07-15 | Dainippon Sumitomo Pharma Co., Ltd. | Oral disintegrating tablet |
US8420662B2 (en) | 2007-04-26 | 2013-04-16 | Toray Industries, Inc. | Stable solid preparation containing 4,5-epoxymorphinan derivative |
WO2008133330A1 (ja) | 2007-04-26 | 2008-11-06 | Toray Industries, Inc. | 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤 |
US9314454B2 (en) | 2007-12-28 | 2016-04-19 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
JP2011513194A (ja) * | 2008-02-29 | 2011-04-28 | 大塚製薬株式会社 | 口腔内崩壊錠 |
WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
US9119820B2 (en) | 2008-06-13 | 2015-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Tablet quickly disintegrating in the oral cavity and method for producing the same |
CN102119034B (zh) * | 2008-06-13 | 2013-05-22 | 大日本住友制药株式会社 | 在口腔中快速崩解的片剂和制备其的方法 |
JP5583012B2 (ja) * | 2008-06-13 | 2014-09-03 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
JP5637624B2 (ja) * | 2009-02-12 | 2014-12-10 | 富士化学工業株式会社 | 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物 |
JPWO2010092828A1 (ja) * | 2009-02-12 | 2012-08-16 | 富士化学工業株式会社 | 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物 |
WO2010092828A1 (ja) * | 2009-02-12 | 2010-08-19 | 富士化学工業株式会社 | 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物 |
WO2011121823A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
JPWO2011121824A1 (ja) * | 2010-03-29 | 2013-07-04 | アステラス製薬株式会社 | 口腔内崩壊錠 |
JPWO2011121823A1 (ja) * | 2010-03-29 | 2013-07-04 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
JP5614445B2 (ja) * | 2010-03-29 | 2014-10-29 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
WO2011121824A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 口腔内崩壊錠 |
JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
US8642648B2 (en) | 2011-01-17 | 2014-02-04 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
US8642649B2 (en) | 2011-01-17 | 2014-02-04 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
WO2017115764A1 (ja) * | 2015-12-28 | 2017-07-06 | 日本新薬株式会社 | 圧縮成型製剤 |
WO2019146642A1 (ja) * | 2018-01-24 | 2019-08-01 | 大原薬品工業株式会社 | γ-アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法 |
JPWO2019146642A1 (ja) * | 2018-01-24 | 2020-12-10 | 大原薬品工業株式会社 | γ−アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法 |
JP7138666B2 (ja) | 2018-01-24 | 2022-09-16 | 大原薬品工業株式会社 | γ-アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2001248751A1 (en) | 2001-10-23 |
JP4802436B2 (ja) | 2011-10-26 |
JP2011225588A (ja) | 2011-11-10 |
JPWO2001076565A1 (ja) | 2004-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4802436B2 (ja) | 口腔内崩壊型組成物及び口腔内崩壊型製剤 | |
RU2189227C2 (ru) | Быстро распадающиеся прессованные в формах материалы и способ их получения | |
RU2478375C2 (ru) | Распадающаяся во рту таблетка | |
JP4336021B2 (ja) | 口腔内崩壊型錠剤およびその製造法 | |
US9089490B2 (en) | Orally disintegrating tablets and methods of manufacture | |
US8956650B2 (en) | Intrabuccally rapidly disintegrating tablet and a production method of the tablets | |
JP4551092B2 (ja) | 口腔内速崩壊性錠剤 | |
JP4365095B2 (ja) | 口腔内速崩壊錠 | |
US20100285164A1 (en) | Orally Disintegrating Excipient | |
TW201022253A (en) | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof | |
KR20130030306A (ko) | 약학 조성물 | |
JPH1192387A (ja) | シメチコン/無水燐酸カルシウム組成物 | |
JP2006306891A (ja) | ポリマーベースの迅速に溶解する錠剤およびその生成プロセス | |
WO2006123678A1 (ja) | ドロキシドパを含有する安定な錠剤 | |
WO2007029376A1 (ja) | 口腔内速崩壊性錠剤 | |
JP7336388B2 (ja) | 錠剤及びその製造方法 | |
JP3900245B2 (ja) | 口腔内速崩壊型錠剤及びその製造方法 | |
Roshan et al. | Orodispersible tablets: a compendious review | |
JP4358117B2 (ja) | 口腔内速崩壊錠 | |
JP2003176242A (ja) | 速崩壊性圧縮成型物及びその製造法 | |
JP3228335B2 (ja) | 口腔内崩壊型組成物及びその製造方法 | |
JP4601271B2 (ja) | 圧縮成形製剤およびその製造方法 | |
JP2002308760A (ja) | 圧縮成型用組成物及びその利用 | |
WO2017038455A1 (ja) | 超速崩壊錠剤及びその製造方法 | |
JP2002138055A (ja) | 口腔内速崩壊性圧縮成型物およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 574083 Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |